Skip to main content
. Author manuscript; available in PMC: 2018 Nov 1.
Published in final edited form as: J Pharm Sci. 2017 Jun 15;106(11):3293–3302. doi: 10.1016/j.xphs.2017.06.008

Table 1.

Characterization of treatments.

Sample Molar Ratio of LABL:PLP:HA Approximate MW (kDa) Dh in PBS (nm)
Hyaluronic Acid (HA) graphic file with name nihms898133t1.jpg 0:0:1 16 2.4±1.0
Proteolipid Protein (PLP139–151) graphic file with name nihms898133t2.jpg 0:10:0 1.5 N/A
LABL graphic file with name nihms898133t3.jpg 10:0:0 1.0 N/A
Soluble Antigen Array (SAgA) graphic file with name nihms898133t4.jpg 7.5:5.8:1 33 3.7±1.6
Bifunctional Peptide Inhibitor (BPI) graphic file with name nihms898133t5.jpg 1:1:0 3.0 N/A